Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: Cohort B of the phase II KEYNOTE-086 study

Annals of Oncology

Volumn 30, Issue 3, 2019, Pages 405-411

  Adams, S ^a   Loi, S ^b   Toppmeyer, D ^c   Cescon, D W ^d   De Laurentiis, M ^e   Nanda, R ^f   Winer, E P ^g   Mukai, H ^h   Tamura, K ⁱ   Armstrong, A ^j   Liu, M C ^k   Iwata, H ^l   Ryvo, L ^m   Wimberger, P ⁿ   Rugo, H S ^o   Tan, A R ^p   Jia, L ^q   Ding, Y ^q   Karantza, V ^q   Schmid, P ^r  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b PETER MACCALLUM CANCER CENTRE   (Australia)

^c RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

^d UNIVERSITY OF TORONTO   (Canada)

^e NATIONAL CANCER INSTITUTE   (Italy)

^f UNIVERSITY OF CHICAGO   (United States)

^g DANA FARBER CANCER INSTITUTE   (United States)

^h NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

ⁱ NATIONAL CANCER CENTER HOSPITAL   (Japan)

^j CHRISTIE HOSPITAL   (United Kingdom)

^k MAYO CLINIC   (United States)

^l AICHI CANCER CENTER HOSPITAL   (Japan)

^m TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

ⁿ DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^o UNIVERSITY OF CALIFORNIA   (United States)

^p LEVINE CANCER INSTITUTE   (United States)

^q MERCK RESEARCH LABORATORIES   (United States)

^r QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

more..

Author keywords

anti PD 1; immunotherapy; pembrolizumab; triple negative breast neoplasms

Indexed keywords

ANTHRACYCLINE DERIVATIVE; LACTATE DEHYDROGENASE; PEMBROLIZUMAB; PROGRAMMED DEATH 1 RECEPTOR; TAXANE DERIVATIVE; CD274 PROTEIN, HUMAN; MONOCLONAL ANTIBODY; PROGRAMMED DEATH 1 LIGAND 1;

ADJUVANT THERAPY; ADRENAL INSUFFICIENCY; ADULT; AGED; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER MORTALITY; COHORT ANALYSIS; COLITIS; DECREASED APPETITE; DIARRHEA; DISEASE CONTROL; DISEASE FREE INTERVAL; DISEASE SEVERITY; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEMALE; HUMAN; HYPERTHYROIDISM; HYPOTHYROIDISM; INFUSION RELATED REACTION; MAJOR CLINICAL STUDY; MALE; NAUSEA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PRURITUS; RASH; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; TRIPLE NEGATIVE BREAST CANCER; VERY ELDERLY; VOMITING; CLINICAL TRIAL; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETICS; METASTASIS; MIDDLE AGED; PATHOLOGY; PHASE 2 CLINICAL TRIAL;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; B7-H1 ANTIGEN; COHORT STUDIES; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PROGRESSION-FREE SURVIVAL; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 85060730715     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdy518     Document Type: Article

References (15)

1. Perou CM, Sørlie T, Eisen MB et al. Molecular portraits of human breast tumours. Nature 2000; 406(6797): 747-752.
2. Robson M, Im SA, Senkus E et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med 2017; 377(6): 523-533.
3. Litton JK, Rugo HS, Ettl J et al. Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. N Engl J Med 2018; 379(8): 753-763.
4. Bianchini G, Balko JM, Mayer IA et al. Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease. Nat Rev Clin Oncol 2016; 13(11): 674-690.
5. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012; 12(4): 252-264.
6. Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 2008; 26: 677-704.
7. Mittendorf EA, Philips AV, Meric-Bernstam F et al. PD-L1 expression in triple-negative breast cancer. Cancer Immunol Res 2014; 2(4): 361-370.
8. Schalper KA, Velcheti V, Carvajal D et al. In situ tumor PD-L1 mRNA expression is associated with increased TILs and better outcome in breast carcinomas. Clin Cancer Res 2014; 20(10): 2773-2782.
9. Wimberly H, Brown JR, Schalper K et al. PD-L1 expression correlates with tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy in breast cancer. Cancer Immunol Res 2015; 3(4): 326-332.
10. Ali HR, Glont SE, Blows FM et al. PD-L1 protein expression in breast cancer is rare, enriched in basal-like tumours and associated with infiltrating lymphocytes. Ann Oncol 2015; 26(7): 1488-1493.
11. Nanda R, Chow LQ, Dees EC et al. Pembrolizumab in patients with advanced triple-negative breast cancer: phase Ib KEYNOTE-012 study. J Clin Oncol 2016; 34(21): 2460-2467.
12. Adams S, Schmid P, Rugo HS et al. Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study. Ann Oncol 2019; 30(3): 397-404.
13. Schmid P, Adams S, Rugo HS et al. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. N Engl J Med 2018; 379(22): 2108-2121.
14. Garon EB, Rizvi NA, Hui R et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 2015; 372(21): 2018-2028.
15. Robert C, Ribas A, Wolchok JD et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet 2014; 384(9948): 1109-1117.